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Background: Artemether-lumefantrine (AL) dispersible formulation was developed for the treatment of uncomplicated
Plasmodium falciparum malaria in infants and children weighing 5 to <35 kg. However, there are no clinical studies with
artemisinin-based combination therapy in infants <5 kg.
Methods: This multicentre, open-label, single-arm study evaluated the efficacy, safety and pharmacokinetics of AL
dispersible in infants aged >28 days and <5 kg of body weight, who were treated with one AL dispersible tablet
(20 mg artemether/120 mg lumefantrine) given twice-daily for three days and followed up for six weeks (core
follow-up) and at 12 months of age (long-term follow-up).
Results: A total of 20 patients were enrolled and completed the six-week core study follow-up. In the per protocol
population, PCR-corrected cure rate at days 28 and 42 was 100% (95% CI: 79.4, 100). AL dispersible was well tolerated
with reported adverse events of mild to moderate severity. Pharmacokinetic data showed that lumefantrine levels were
similar, however, artemether and dihydroartemisinin levels were on average two- to three-fold greater than historical
values in infants and children ≥5 kg.
Conclusions: A three-day regimen of AL dispersible formulation was efficacious and generally well tolerated in infants
weighing <5 kg with uncomplicated P. falciparum malaria, but artemether and dihydroartemisinin exposures could not
be supported by the preclinical safety margins for neurotoxicity. Hence, dosing recommendations cannot be made in
infants <5 kg as implications for toxicity are unknown.
Trial Registration: Clinicaltrials.gov NCT01619878.
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Artemether-lumefantrine ((AL) Coartem®/Riamet®, Novartis
Pharma AG, Basel, Switzerland) is the first fixed-dose
artemisinin-based combination therapy (ACT) to be pre-
qualified by the World Health Organization for the treat-
ment of uncomplicated Plasmodium falciparum malaria in
adults and children weighing ≥5 kg [1-3]. The paediatric* Correspondence: kamal.hamed@novartis.com
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unless otherwise stated.formulation of AL (AL dispersible), tailored to the needs of
infants and children weighing 5 to <35 kg, is a sweet tasting
and easy-to-administer formulation. Since its launch in
2009, >250 million AL dispersible treatments have been de-
livered to over 50 malaria-endemic countries. AL dispers-
ible was tested in a large multicentre trial in 899 children
and was found to be as efficacious as crushed tablet, with a
similar safety profile [4]. The efficacy of AL dispersible was
similar across different body weight dosing groups [5], and
the formulation was easier to use and more acceptable, as
compared with the crushed tablet in children [6,7].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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children weighing ≥5 kg, there are no clinical trials or na-
tional guidelines for treatment of infants <5 kg. The current
treatment for this subgroup is oral quinine, which is associ-
ated with a poor safety profile [8]. Other anti-malarial treat-
ments are frequently used off-label, on the basis of
recommended dosing schedules for older infants and chil-
dren [9,10]. Although some studies have reported ACT use
in this subgroup [9], no ACT has been approved for
use in infants <5 kg, with the exception of artesunate-
amodiaquine, which is registered for the treatment of
infants ≥4.5 kg. Thus, there is an unmet medical need
in infants <5 kg with uncomplicated P. falciparum
malaria. This study aimed to evaluate the efficacy, safety
and pharmacokinetics (PK) of AL dispersible following
treatment with a three-day regimen in infants <5 kg with
uncomplicated P. falciparum malaria.
Methods
Patients
Male and female infants aged >28 days and weighing <5
kg, with microscopically confirmed acute uncomplicated
P. falciparum malaria, including asexual P. falciparum
parasitaemia >1,000 and <100,000 parasites/μL, were in-
cluded. Patients were recruited from three healthcare fa-
cilities in two countries in Africa, one in Benin and two in
Burkina Faso. Patients with severe malaria or general
danger signs (i.e., signs of a critical condition or severely
deteriorated general condition) based on the Integrated
Management for Childhood Illnesses (IMCI) criteria for
sick infants were excluded from the study. The trial proto-
col was approved by an Independent Ethics Committee
(IEC) and the Institutional Review Board (IRB) at each
study centre (a Swiss IEC and two local IRBs). Signed in-
formed consent was obtained from parent or legal guard-
ian before any study-related procedure. The study was
conducted in accordance with the International Confer-
ence on Harmonization Guidelines for Good Clinical
Practice, Declaration of Helsinki, and local regulations of
each participating country. This trial is registered with
with ClinicalTrials.gov number NCT01619878.
Study design
This multicentre, open-label, single-arm study was planned
to be conducted in two sequential cohorts of infants
<5 kg; cohort 1 in infants >28 days old and cohort 2 in
neonates ≤28 days of age. Based on an interim analysis of
cohort 1 results after the six-week core follow-up period,
cohort 2 was not initiated as recommended by a data
monitoring committee. The study was terminated after
all patients from cohort 1 completed their long-term
follow-up.
Patients were admitted to the hospital during a three-
day treatment phase and followed up until day 42 (week6) after treatment, with regular assessments for efficacy
and safety during the six weeks. A long-term follow-up
was conducted at 12 months of age to assess neurodeve-
lopmental status. Patients in cohort 1 received directly
observed treatment of AL dispersible tablet (20 mg arte-
mether/120 mg lumefantrine) following a regimen of
one dispersible tablet twice daily for three consecutive
days. The consumption of food or drink (mother’s or
formula milk) was recommended after dose to enhance
lumefantrine absorption. In the event of vomiting within
an hour of dosing, a repeat dose was administered and a
maximum of two doses were replaced throughout the
entire treatment phase.
Patients who developed severe malaria or early treat-
ment failure signs were to receive rescue therapy as per
local treatment guidelines. Presence of parasitaemia on
day 7, irrespective of clinical state, and vomiting of replace-
ment dose within one hour warranted rescue therapy.
Study assessments
Clinical and parasitological examinations were performed
on days 0, 1, 2, 3, 7, 28, and 42. Giemsa-stained thick and
thin smears were examined locally at each visit using a
light binocular microscope fitted with an oil immersion
lens for assessment of parasitaemia. Blood smears were
also systematically read at a central facility. Blood samples
for molecular diagnostics (PCR-based methods) were
taken at baseline, days 14, 28 and 42, and at any unsched-
uled visit when reappearance of parasitaemia was con-
firmed microscopically.
Physical examination was performed on days 2, 3, 4, 7,
14, 28, and 42, or at the time of withdrawal. Vital signs
including systolic and diastolic blood pressure (measured
with Dynascope DS-7100, Fukuda Denshi Co., Tokyo,
Japan, with an appropriately sized cuff ), temperature,
and pulse rate were measured. Blood samples were col-
lected and analysed locally for haematology and blood
chemistry tests.
Safety monitoring included recording of all adverse
events (AEs) and serious AEs (SAEs). Neurodevelop-
mental status was assessed using an age-appropriate
scale (Shoklo neurodevelopmental scale) at 12 months
of age [11].
Blood samples (250 μL each) were drawn at predefined
timepoints: one and two hours after the first AL dose for
measurement of artemether and its active metabolite
dihydroartemisinin (DHA) in plasma; six hours after the
fifth and sixth doses, 24 hours after the sixth dose, and
on day 7 for lumefantrine measurement. Artemether
and DHA were analysed using reversed-phase HPLC
with MS/MS detection and the limit of quantification
(LOQ) was 5 ng/mL. Lumefantrine was determined
using reversed-phase HPLC with MS/MS detection and
the LOQ was 50 ng/L.
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It was aimed to enroll 40 patients to obtain a sample
size of at least 30 patients evaluable for the primary end-
point (at least 15 evaluable patients in each cohort).
Based on an assumed PCR-corrected day 28 cure rate of
95% and a sample size of 30 evaluable patients, the study
had 80% power to result in an estimate of cure rate asso-
ciated with a lower exact 95% confidence limit >77%.
For secondary efficacy variables, Exact Pearson-Clopper
two-sided 95% confidence limits were constructed for
dichotomous outcome variables (cure rates at days 3, 7,
14, 28, and 42). Incidence of gametocyte carriage over
time was summarized by baseline gametocyte carriage
status.
Descriptive summary statistics were presented for values
and change from baseline to each follow-up. For PK ex-
posure to artemether, DHA and lumefantrine, descriptive
statistics of concentrations at discrete timepoints were
presented. However, no formal PK analysis was performed
due to limited number of sample points.
The infant neurodevelopmental scale included the
total scores for motor milestones (section A), coordin-
ation (section B), tone (section C), behaviours (section
D), and the sum of all sections together. All patients
who received at least one dose of the study drug and
had confirmed falciparum malaria at baseline were
included in the full analysis set (FAS). The evaluable
patient set (EPS) comprised patients from the FAS who
had a known 28-day cure status, i.e., those who completed
the study at least until day 28, or were considered failures
before day 28 for reasons other than premature with-
drawal. Patients from the EPS weighing <5 kg at baseline,
who took at least five of six doses of the study drug, had
baseline asexual parasite counts >1,000 and <100,000 par-
asites/μL based on central microscopy reading, and did
not take any other medication with anti-malarial effect
(excluding rescue medication) up to day 28 were
included in the per protocol set (PPS).Enrolled
(n=20)
Completed long-term follow-up 




    Adverse event (n=1)
Discontinued study
Death (n=2)
Lost to follow-up (n=1)
Completed 6-week core 
follow-up period
(n=20)
Figure 1 Subject disposition.Outcome measures
PCR-corrected parasitological cure rate at day 28 was the
primary efficacy outcome defined as the proportion of pa-
tients clearing asexual parasites within seven days of initiat-
ing the study treatment without recrudescence before or at
day 28, corrected for re-infection using PCR. The secondary
efficacy outcomes included PCR-corrected parasitological
cure rates at days 14 and 42 and uncorrected cure rates at
days 3, 7, 14, 28, and 42.
Artemether, DHA and lumefantrine concentrations
were determined at discrete timepoints during and after
treatment with AL dispersible. Safety parameters included
incidence of AEs, SAEs and routine safety laboratory
assessments.Results
A total of 20 infants were recruited into the study and
completed the six-week core follow-up. One patient discon-
tinued study treatment because of vomiting but remained
in the study. No patients received rescue therapy. A total of
17 patients completed the long-term follow-up visit at
12 months of age (Figure 1). Cohort 2 was not initiated as
recommended by the data monitoring committee due to
increased artemether and dihydroartemisinin exposures ob-
served during an interim analysis and the potential risk of
neurotoxicity based on preclinical data.
The median age (range) was 82 (37-214) days and me-
dian body weight (range) was 4.8 (2.6-4.9) kg. There was
an equal number of male and female patients, and all pa-
tients were of African origin. The patients’ demographic
and baseline characteristics are shown in Table 1.
The PCR-corrected cure rate on days 14, 28 and 42 was
100% in the EPS and PPS populations (95% confidence
interval (CI): 79.4-100), whereas it was 80% for the FAS
population (95% CI: 56.3-94.3). Four patients did not have
a microscopy reading after day 7 and were hence conser-
vatively classified as treatment failures. The uncorrected
cure rate on day 14 was also 100% (95% CI: 79.4-100;
79.4-100) in the EPS and PPS populations. However, the
uncorrected cure rates were lower on days 28 and 42 in
all populations (Table 2). The mean time to asexual para-
site clearance was 29.1 ± 9.6 and 30.7 ± 8.8 hours in the
FAS and EPS/PPS populations, respectively. Only one
patient was infected with Plasmodium ovale in addition to
P. falciparum at baseline, which persisted up to 72 hours
and cleared. AL dispersible rapidly cleared fever with a
mean time to fever clearance of 4.0 ± 6.4 and 4.1 ±
7.0 hours in the FAS and EPS/PPS populations, respect-
ively. Complete (100%) asexual parasite clearance was
achieved by 48 hours (Figure 2) and fever clearance by
26 hours (Figure 3). The mean gametocyte clearance time
was 36.3 ± 77.3 and 43.9 ± 85.1 hours in the FAS and EPS/
PPS populations, respectively. AL dispersible rapidly
cleared gametocytes over time. By eight hours on day 1,
gametocyte clearance was 90 and 87.5% in the FAS and
EPS/PPS populations, respectively. After 24 hours, 20% of
Table 1 Demographics and baseline characteristics
Parameters N = 20
Age (days)
>28 days, n (%) 20 (100)












Mean ± SD 56.6 ± 4.1
Median 56.0
Min-max 48-65
Parasite species, n (%)
Plasmodium falciparum 20 (100)
Plasmodium ovale 1 (5)
Others 0 (0)
Plasmodium falciparum asexual forms (/μL) n = 20
Mean ± SD 13,783.6 ± 19,214.5
Median 7,273
Min-max 1,014-84,147
Plasmodium falciparum density categories, n (%)
1,000-5,000/μL 8 (40)
>5,000 12 (60)
Plasmodium falciparum gametocytes (/μL) n = 3
Mean ± SD 606.7 ± 640.8
Median 481
Min-max 38-1,301
Body temperature (°C) n = 20
Mean ± SD 37.5 ± 0.9
Median 37.2
Min-max 36.0-39.0
Max, maximum; Min, minimum; SD, standard deviation.
Table 2 Parasitological cure rates on days 14, 28 and 42
Population PCR-corrected cure rates PCR-uncorrected cure rates
n (%) n (%)
(95% CI) (95% CI)
Day 14
FAS (N = 20) 16 (80) 16 (80)
(53.6, 94.3) (53.6, 94.3)
EPS (N = 16) 16 (100) 16 (100)
(79.4, 100) (79.4, 100)
PPS (N = 16) 16 (100) 16 (100)
(79.4, 100) (79.4, 100)
Day 28
FAS (N = 20) 16 (80) 10 (50)
(53.6, 94.3) (27.2, 72.8)
EPS (N = 16) 16 (100) 10 (62.5)
(79.4, 100) (35.4, 84.8)
PPS (N = 16) 16 (100) 10 (62.5)
(79.4, 100) (35.4, 84.8)
Day 42
FAS (N = 20) 16 (80) 7 (35)
(53.6, 94.3) (15.4, 59.2)
EPS (N = 16) 16 (100) 7 (43.8)
(79.4, 100) (19.8, 70.1)
PPS (N = 16) 16 (100) 7 (43.8)
(79.4, 100) (19.8, 70.1)
CI, Exact Pearson-Clopper two-sided 95% confidence limits; EPS, evaluable
population set; FAS, full analysis set; PPS, per protocol set.
Parasitaemia results were taken from the central microscopy reading.
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and by the end of 48 hours only one patient had gameto-
cytes. Complete gametocyte clearance was observed by
day 14 in all patients.
There were no deaths or SAEs reported during the
six-week core follow-up period, and all AEs reported
were mild to moderate in severity. At least one AE was
reported by most patients (85%) during the core follow-upperiod. The most frequently reported AEs were new epi-
sodes of uncomplicated malaria (i.e., malaria re-infection)
reported in 55% of patients during the follow-up period,
followed by anaemia (35%; mild 5%, moderate 5%, severe
25%) and bronchitis (30%). Pyrexia, a manifestation of mal-
aria, was also reported as an AE. Vomiting was reported as a
drug-related AE in four (20%) patients (Table 3). One pa-
tient discontinued the study drug because of vomiting on
day 1, which was moderate in intensity. However, this was
not suspected to be related to the study drug and resolved
by day 4. Out of the three SAEs reported during the long-
term follow-up, two patients died and one patient was re-
ported as having cerebral malaria and anaemia. The cerebral
malaria resolved after appropriate treatment with quinine
and antipyretics. A female patient aged 107 days died from
acute diarrhoea with dehydration 52 days after completion
of core follow-up (day 95), but had no prior AE or SAE rec-
ord. Another patient, a 75-day-old male infant, died sud-
denly at home on an unrecorded date due to unknown
etiology, after experiencing anorexia one day before death.
Table 4 shows the proportion of patients with laboratory test
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Parasite clearance time following treatment with AL dispersible
Cohort 1
Figure 2 Parasite clearance time following treatment with artemether-lumefantrine dispersible. AL, artemether-lumefantrine. Parasite clearance
time was defined as the time from first dose until total and continued disappearance of asexual forms for at least a further 48 hours (based on
central microscopy reading). Subjects withdrawn from the study or on rescue medication before parasite clearance or those without parasite
clearance till day 7 were considered censored at the time of withdrawal/start of rescue medication/day 7, whichever occurred earlier.
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from normal to grade 3 or 4 toxicity.
The mean ± SD score on the Shoklo neurodevelopmental
scale for motor milestones (Section A) was 27.1 ± 4.5, co-
ordination (Section B) 24.8 ± 4.6, tone (Section C) 16.6 ±
2.6, and behaviour (Section D) 14.4 ± 1.2. The overall total
score mean ± SD (sum of A, B, C, and D) was 82.8 ± 9.4.
The scores were within the normal range in all four do-
mains of the scale.
The mean artemether and DHA concentrations at one
and two hours post-first dose were two- to three-fold greater
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Figure 3 Fever clearance time following treatment with artemether-lumefa
was defined as the time from first dose until the axillary temperature decre
Subjects who were withdrawn from the study or who received anti-malaria
achieved were considered censored at the time of withdrawal/start of resc(Table 5). Two patients had artemether concentrations
higher than the range observed in infants/children ≥5 kg
(Figure 4). Mean lumefantrine concentrations and range
were similar to historical data in infants/children ≥5 kg ex-
cept at day 7 where the mean lumefantrine concentration
was found to be almost two-fold greater than values seen in
infants ≥5 kg.
Discussion
In the current study that evaluated the efficacy, safety
and PK of AL dispersible in infants aged >28 days and
weighing <5 kg, AL dispersible was efficacious for theng treatment with AL dispersible
 (Hours)
90 100 110 120 130 140 150 160 170 180
Cohort 1
ntrine dispersible. AL, artemether–lumefantrine. Fever clearance time
ased and remained below 37.5οC for at least a further 48 hours.
l rescue medication, within seven days and before the clearance was
ue medication.
Table 3 Most common adverse events
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corrected cure rate (100%) on days 28 and 42 for the EPS
and PPS populations was slightly higher than earlier reports
in infants and children ≥5 kg [4,12]. The uncorrected cure
rates on days 28 and 42 reflect a high intensity of malaria
transmission and high incidence of new infections in the
study sub-region. The response to treatment was rapid in
the study patients with faster mean time to parasite clear-
ance and similar fever clearance to that reported earlier in
children 5 to <10 kg of body weight [5,12].
AL dispersible was well tolerated with no new AEs re-




Haemoglobin Low 1 (6.3)
High 0
Haematocrit Low 1 (6.3)
High 0
Neutrophils Low 3 (18.8)
High 0
Platelets Low 1 (6.3)
High 0
Blood chemistry parameters
Bilirubin (total) Low 1 (6.3)
High 2 (12.5)








SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic tranmalaria and anaemia in the long-term follow-up, all AEs
were mild to moderate in intensity and the most commonly
reported AEs were indicative of signs or symptoms of mal-
aria, in line with previous reports in older infants and chil-
dren [4,12]. As expected in this age group, vomiting was
reported in four patients and was considered a drug-related
AE, as in previous studies [4,5,13]. The two deaths reported
in this study were reported after the core follow-up period
and were deemed unrelated to study medication or to the
index malaria episode. One patient had reported cerebral
malaria and anaemia as SAEs during the long-term follow-
up period, which resolved after treatment and were not
considered to be related to study drug.
Artemether and DHA concentrations, on average, were
found to be two- to three-fold greater in infants <5 kg as
compared with historical levels [14] in older infants and
children ≥5 kg, while those of lumefantrine appeared
similar overall [4]. When combined with the data from
infants and children ≥5 kg, a general trend of increas-
ing exposure to artemether was observed with decreas-
ing age and weight, especially in patients <10 kg and
below the age of ~12 months (Figure 4). Thus, expos-
ure to AL dispersible appears to be a complex function
of both age and weight below the age of 12 months. Sim-
ple allometric scaling (based on relative body surface areaormalities
Day 7 Day 14 Day 28 Day 42
n (%) n (%) n (%) n (%)
2 (10.5) 1 (8.3) 1 (12.5) 1 (25.0)
0 0 0 0
1 (5.3) 1 (8.3) 1 (12.5) 0
0 0 0 0
3 (17.6) 2 (20.0) 2 (25.0) 0
1 (5.9) 0 0 1 (25.0)
1 (6.3) 1 (10.0) 1 (12.5) 0
4 (25.0) 5 (50.0) 0 2 (50.0)
0 0 0
0 0 0
3 (18.8) 0 0
1 (6.3) 0 0
0 0 0






Table 5 Pharmacokinetic exposure of artemether, dihydroartemisinin, and lumefantrine: comparison with historical
data from older infants and children
Time point
post-first dose
Current study Historical data
Mean ± SD (CV %) [n] Range Mean ± SD (CV %) [n] Range
Artemether concentration (ng/mL)
1 h 446 ± 321 (72%) [15] 19.7-1210 139 ± 160 (116%) [173] 0-932
2 h 380 ± 262 (68%) [18] 0-933 140 ± 122 (87%) [170] 0-776
Dihydroartemisinin concentration (ng/mL)
1 h 87.6 ± 58.9 (67%) [15] 7.2-202 46.0 ± 54.2 (118%) [177] 0-345
2 h 93.4 ± 67.0 (72%) [18] 0-252 57.4 ± 57.5 (100%) [178] 0-429
Lumefantrine concentration (μg/mL)
30 h No sample taken 5.29 ± 4.28 (81%) [63] 0-23.7
54 h 6.50 ± 3.37 (52%) [17] 0.819-12.5 5.84 ± 4.28 (73%) [62] 0.524-21.4
66 h 6.04 ± 2.77 (45%) [17] 2.27-12.8 6.98 ± 5.29 (76%) [323] 0.069-42.0
84 h 3.40 ± 2.28 (67%) [17] 1.16-8.72 3.02 ± 2.08 (69%) [49] 0.010-7.80
168 h (Day 7) 0.815 ± 0.567 (70%) [16] 0.200-2.39 0.386 ± 0.326 (84%) [63] 0-1.71
336 h No sample taken 0.541 ± 2.13 (394%) [65] 0-12.2
CV, coefficient of variation; h, hour; SD, standard deviation.
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doses (20 mg artemether and 120 mg lumefantrine twice
daily for three days) used in this study are on the higher
side for infants <5 kg. However, the available lumefantrine
model from older children and adults cannot be used to
derive a new dose recommendation for the fixed-dose
combination of AL, because of an inherent complexity in
predicting exposure in young infants and neonates [15].
Infants and neonates have different maturation stages for
the absorption, distribution and disposition paths of arte-
mether, DHA and lumefantrine, making predictions unre-
liable in this sub-population.
Artemether exposure was consistently high in in-
fants <5 kg and aged less than three months, and in-
fants with the lowest body weight and age had the highest
exposure. Artemether undergoes a high first pass metabol-
ism and is predominantly metabolized by the CYP3A4 en-
zyme [16]. CYP3A4 is present both in the gut and liver
and is reported to have low activity in infants <12 months
of age [15], particularly during the first week of life [17].
Hence, higher artemether exposure in infants could
be primarily caused by immature CYP3A4 metabol-
ism. Further decrease in the CYP3A4 activity in neo-
nates ≤28 days would be expected to increase artemether
exposure disproportionally.
DHA concentrations also increased, though to a lesser
extent than artemether. This could result from the different
metabolic pathways and the relatively lower first pass effect
of DHA. DHA undergoes metabolism by glucuronidation,
predominantly by UGT1A9 and UGT2B7, which are
mostly hepatic. UGTs have decreased activity in newbornsand young children as compared with adolescents and
adults [15]. In neonates, there could be a significantly lower
activity of these metabolic enzymes.
Given the known neurotoxic effects of artemisinins in
animal studies [18-20], the neurologic safety of AL has
been of interest in several human studies. Neurotoxicity
has only been reported after intramuscular artemether ad-
ministration in adult rats at 25 mg/kg/day for seven to14
days and in adult dogs at doses ≥20 mg/kg/day for eight
days, but its relevance to neonates/infants is unknown. Al-
though artemisinins have been known to cause neurotoxic
effects in animals [18-20], there is no conclusive evidence
of neurotoxic effects in adults or children [4,21]. Further,
neurotoxicity has not been observed after oral artemether
administration [22], suggesting that it is the total exposure
over an extended period that leads to this toxicity, which
can occur with intramuscular administration because of
its slow continuous absorption without first pass effect.
However, it was not possible to calculate reliable AUC in
infants in this study because of the limitations in both the
number and total volume of blood samples obtained from
this population.
Higher exposures (Cmax and AUC) and greater sys-
temic toxicity with decreasing age of rat pups after arte-
mether oral administration were reported [22]. Greater
systemic toxicity was observed in the younger animals
(mortality in seven to 13-day-old pups started at 30 mg/
kg/day dose but no mortality in older pups was observed
at this dose). In adult rats, neither mortality nor clinical
neurotoxicity was observed at equivalent or higher arte-
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Figure 4 Comparison of artemether (a) and dihydroartemisinin (b) exposure in different age and body weight groups.
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fants with a body weight <5 kg may be at particular risk for
toxicity not observed in children or adults.
The age-appropriate Shoklo neurodevelopmental scale
assessment that was performed at the long-term follow-up
visit was selected as it focused on coordination and concen-
tration, two areas where the neurological adverse effects of
artemisinins are expected. The mean and median behaviour
scores were close to the maximum possible value observed
earlier [23]; the median to lower limit of range scores for
coordination or behaviour milestones at 12 months were
comparable to the Karen ethnic minority or the London
cohorts [11]. The same variables were slightly higher for
tone milestones in this study. This test was administered to
children once, at the age of 12 months, in this study con-
sisting of a single treatment arm. Thus, the present study
cannot provide a baseline for comparison between different
ages nor data from a comparative arm. Further, although
the Shoklo scale was developed for countries with limited
healthcare resources, the limitations of the present study
mean that these results must be viewed with caution.
AL is a fixed-dose combination treatment, meaning
that adjusting the dose of artemether by giving fractional
doses of the dispersible tablet while maintaining that of
lumefantrine unchanged is not feasible. The dispersible
tablet neither has a break score nor is suitable for split-
ting, and the dispersion formed is not homogenous.
Thus, half the quantity of artemether and lumefantrine
cannot be guaranteed with approximately half of a dis-
persible tablet or half an aliquot of the dispersion. Dose
adjustment with one dispersible tablet administered once
daily for three days may also not reduce the risk of po-
tential artemether and DHA toxicity as the Cmax values
would remain elevated. Lumefantrine exposure is the
principal determinant of AL anti-malarial activity [24],
which drives the 28-day cure rate. A decrease in lumefan-
trine dose and exposure by using a fractional dose might
put the patients at risk of treatment failure. Thus, on this
basis, clear dosing recommendations cannot be made in
this population of neonates and infants weighing <5 kg.
Conclusion
The three-day regimen of the dispersible tablet formula-
tion of AL was similar in efficacy to that in older infants
and was well tolerated for uncomplicated falciparum
malaria treatment in infants <5 kg of body weight and
aged >28 days, with no new safety findings. On average,
artemether and DHA (but not lumefantrine) systemic
exposures were two- to three-fold greater for patients in
this study as compared to infants and children ≥5 kg.
Although no neurotoxicity has been reported after oral
doses, implications for potential toxicity in infants and
neonates are unknown. Therefore, based on the results
of the current study, clear dosing recommendationscannot be made in infants <5 kg. Furthermore, the
findings from this study underscore the need for de-
tailed characterization of the pharmacokinetic/pharmaco-
dynamic and safety profile of ACT and other anti-malarial
drugs for use in this population to determine optimal
doses rather than relying on empirical doses.
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